LLY

745.95

-1.14%↓

JNJ

177.42

-0.37%↓

ABBV

214.73

-1.64%↓

UNH

348.54

-1.24%↓

AZN

77.58

-2.46%↓

LLY

745.95

-1.14%↓

JNJ

177.42

-0.37%↓

ABBV

214.73

-1.64%↓

UNH

348.54

-1.24%↓

AZN

77.58

-2.46%↓

LLY

745.95

-1.14%↓

JNJ

177.42

-0.37%↓

ABBV

214.73

-1.64%↓

UNH

348.54

-1.24%↓

AZN

77.58

-2.46%↓

LLY

745.95

-1.14%↓

JNJ

177.42

-0.37%↓

ABBV

214.73

-1.64%↓

UNH

348.54

-1.24%↓

AZN

77.58

-2.46%↓

LLY

745.95

-1.14%↓

JNJ

177.42

-0.37%↓

ABBV

214.73

-1.64%↓

UNH

348.54

-1.24%↓

AZN

77.58

-2.46%↓

Home・Akcijų sąrašas・Essa Pharma Inc

Essa Pharma Inc

Atidarymo kaina

0.19 -5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.16

Max

0.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.4M -4M
Pelnas, tenkantis vienai akcijai	-0.14
Dividendų pajamingumas	87.56
Pelno marža	-4,681.422
Darbuotojai	35
EBITDA	1.4M -5M

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	87.56% 3.12%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-73M 11M
Ankstesnė atidarymo kaina	5.19
Ankstesnė uždarymo kaina	0.19

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.7 / 1.72 Palaikymas ir pasipriešinimas

Essa Pharma Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-12 22:41; UTC

Pagrindinės rinkos jėgos

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

2025-09-12 16:04; UTC

Pagrindinės rinkos jėgos

Upexi Shares Climb on Solana Gains

2025-09-14 23:48; UTC

Rinkos pokalbiai

Oil Futures Mixed Amid Divergent Signals -- Market Talk

2025-09-14 23:41; UTC

Rinkos pokalbiai

Gold Edges Lower on Likely Technical Correction -- Market Talk

2025-09-14 23:38; UTC

Rinkos pokalbiai

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

2025-09-14 23:13; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-14 23:04; UTC

Rinkos pokalbiai

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

2025-09-13 08:20; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-09-12 20:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-09-12 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-12 20:09; UTC

Uždarbis

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

2025-09-12 19:23; UTC

Rinkos pokalbiai

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025-09-12 19:16; UTC

Rinkos pokalbiai

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

2025-09-12 19:03; UTC

Rinkos pokalbiai

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

2025-09-12 18:59; UTC

Rinkos pokalbiai

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

2025-09-12 18:38; UTC

Rinkos pokalbiai

Uždarbis

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

2025-09-12 18:33; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

2025-09-12 18:22; UTC

Rinkos pokalbiai

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

2025-09-12 16:56; UTC

Rinkos pokalbiai

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

2025-09-12 16:22; UTC

Uždarbis

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

2025-09-12 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-12 16:19; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

2025-09-12 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-12 16:11; UTC

Uždarbis

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

2025-09-12 15:37; UTC

Rinkos pokalbiai

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

2025-09-12 15:22; UTC

Rinkos pokalbiai

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

2025-09-12 15:07; UTC

Įsigijimai, susijungimai, perėmimai

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Essa Pharma Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Essa Pharma Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.7 / 1.72Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.